MY144613A - Formulations of suberoylanilide hydroxamic acid and methods for producing same - Google Patents

Formulations of suberoylanilide hydroxamic acid and methods for producing same

Info

Publication number
MY144613A
MY144613A MYPI20062258A MYPI20062258A MY144613A MY 144613 A MY144613 A MY 144613A MY PI20062258 A MYPI20062258 A MY PI20062258A MY PI20062258 A MYPI20062258 A MY PI20062258A MY 144613 A MY144613 A MY 144613A
Authority
MY
Malaysia
Prior art keywords
hydroxamic acid
suberoylanilide hydroxamic
formulations
methods
producing same
Prior art date
Application number
MYPI20062258A
Other languages
English (en)
Inventor
Jeannie Chow Wong
Hsien-Hsin Tung
Qingxi Wang
Benjamin Max Cohen
Vincent R Capodanno
Brian Sell
Thomas A Miller
Aaron S Cote
Erik A Dienemann
Kimberly Gallagher
Craig Ikeda
Justin Moser
Pavol Rajniak
Robert A Reed
Cindy Starbuck
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY144613(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MY144613A publication Critical patent/MY144613A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI20062258A 2005-05-20 2006-05-17 Formulations of suberoylanilide hydroxamic acid and methods for producing same MY144613A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US69312805P 2005-06-23 2005-06-23

Publications (1)

Publication Number Publication Date
MY144613A true MY144613A (en) 2011-10-04

Family

ID=37452585

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20062258A MY144613A (en) 2005-05-20 2006-05-17 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Country Status (20)

Country Link
US (4) US8093295B2 (OSRAM)
EP (2) EP2292221A3 (OSRAM)
JP (2) JP5264174B2 (OSRAM)
KR (2) KR100993135B1 (OSRAM)
AR (1) AR055953A1 (OSRAM)
AU (3) AU2006249440C1 (OSRAM)
BR (1) BRPI0605893A (OSRAM)
CA (1) CA2580367C (OSRAM)
CR (1) CR8912A (OSRAM)
DO (1) DOP2006000113A (OSRAM)
EC (1) ECSP077263A (OSRAM)
IL (1) IL181070A0 (OSRAM)
MA (1) MA28804B1 (OSRAM)
MX (1) MX2007002047A (OSRAM)
MY (1) MY144613A (OSRAM)
NI (1) NI200700031A (OSRAM)
NZ (2) NZ594669A (OSRAM)
PE (1) PE20061390A1 (OSRAM)
TW (2) TWI365068B (OSRAM)
WO (2) WO2006127319A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
NZ592686A (en) 2008-10-15 2012-12-21 Generics Uk Ltd Process for the preparation of vorinostat from aniline, hydroxylamine and suberic acid starting materials
WO2010061220A2 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Novel processes and pure polymorphs
CN102282126A (zh) * 2008-11-26 2011-12-14 基因里克斯(英国)有限公司 多晶型物
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
WO2018011811A2 (en) * 2016-07-13 2018-01-18 Rappaport Family Institute For Research In The Medical Sciences Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
KR20010080142A (ko) 1998-10-13 2001-08-22 후지야마 아키라 사이클릭 테트라펩티드 화합물 및 이의 용도
KR20020007398A (ko) 1999-05-03 2002-01-26 추후제출 히스톤 탈아세틸화효소의 억제
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
BR0014254A (pt) 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
KR20070053362A (ko) 1999-11-23 2007-05-23 메틸진, 인크. 히스톤 디아세틸라제의 억제제
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ525439A (en) 2000-09-29 2004-11-26 Topotarget Uk Ltd Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2002102323A2 (en) 2001-06-14 2002-12-27 Bristol-Myers Squibb Company Novel human histone deacetylases
JP4638148B2 (ja) 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US20040132643A1 (en) 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
AU2003219803B8 (en) 2002-02-15 2005-08-25 Sloan-Kettering Institute For Cancer Research Method of treating TRX mediated diseases
US20070060614A1 (en) 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20060276547A1 (en) 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
EP2266552A3 (en) 2002-03-04 2011-03-02 Merck HDAC Research, LLC Methods of inducing terminal differentiation
CN100566711C (zh) 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
EP1567142A4 (en) 2002-11-20 2005-12-14 Errant Gene Therapeutics Llc TREATMENT OF PULMONARY CELLS WITH HISTONE DEACETYLASE INHIBITORS
CN1839121A (zh) 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
CA2535806C (en) * 2003-08-26 2009-02-17 Aton Pharma, Inc. The use of hdac inhibitors for the treatment of cancer
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
US20090227674A1 (en) 2005-08-18 2009-09-10 Richon Victoria M Combination methods fo saha and targretin for treating cancer
EP1942884A4 (en) 2005-11-04 2010-01-06 Merck & Co Inc METHOD FOR THE TREATMENT OF CANCER WITH SAHA, CARBOPLATIN AND PACLITAXEL AND OTHER COMBINATION THERAPIES
CN101300015A (zh) 2005-11-04 2008-11-05 默克公司 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法
US20070197473A1 (en) 2005-11-04 2007-08-23 Frankel Stanley R Methods of using SAHA and Bortezomib for treating cancer

Also Published As

Publication number Publication date
WO2006127321A2 (en) 2006-11-30
EP2292221A3 (en) 2011-08-10
US20080132575A1 (en) 2008-06-05
IL181070A0 (en) 2007-07-04
DOP2006000113A (es) 2006-10-31
AU2009201652B2 (en) 2011-10-06
KR20080113135A (ko) 2008-12-26
CA2580367A1 (en) 2006-11-30
US8288440B2 (en) 2012-10-16
ECSP077263A (OSRAM) 2007-04-26
MX2007002047A (es) 2007-04-12
PE20061390A1 (es) 2007-01-15
AU2010201359A1 (en) 2010-04-29
AR055953A1 (es) 2007-09-12
JP5264174B2 (ja) 2013-08-14
WO2006127319A2 (en) 2006-11-30
JP2011251985A (ja) 2011-12-15
EP1853245A2 (en) 2007-11-14
US8450372B2 (en) 2013-05-28
AU2006249440B2 (en) 2009-03-12
AU2009201652A1 (en) 2009-05-21
AU2009201650A1 (en) 2009-05-21
NI200700031A (es) 2008-03-03
EP2292221A2 (en) 2011-03-09
AU2006249440A1 (en) 2006-11-30
KR100993135B1 (ko) 2010-11-10
TWI365068B (en) 2012-06-01
CR8912A (es) 2008-02-21
US20100113829A1 (en) 2010-05-06
US8093295B2 (en) 2012-01-10
US20100112046A1 (en) 2010-05-06
TW200727892A (en) 2007-08-01
MA28804B1 (fr) 2007-08-01
KR20070062505A (ko) 2007-06-15
KR100884500B1 (ko) 2009-02-20
AU2009201650B2 (en) 2011-09-15
NZ553204A (en) 2011-09-30
TW201034660A (en) 2010-10-01
CA2580367C (en) 2012-08-21
AU2006249440C1 (en) 2009-08-13
JP2008519081A (ja) 2008-06-05
WO2006127319A3 (en) 2007-03-29
TWI415603B (zh) 2013-11-21
US20100119596A1 (en) 2010-05-13
BRPI0605893A (pt) 2007-12-18
WO2006127321A3 (en) 2007-03-22
NZ594669A (en) 2013-02-22
JP5308486B2 (ja) 2013-10-09

Similar Documents

Publication Publication Date Title
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
UA105078C2 (uk) Фармацевтична композиція, яка містить тетрагідрофолієву кислоту
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
MY174452A (en) Substituted piperidines that increase p53 activity and the uses thereof
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
WO2007021970A3 (en) Stable pharmaceutical formulations and methods of use thereof
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
NI200700031A (es) Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas
EP1993567A4 (en) PER OS ADMINISTRABLE GALLIUM PREPARATIONS AND METHODS OF USE
NZ591204A (en) Pharmaceutical compositions and methods for stabilizing the same
NO20070952L (no) Formuleringer av suberoylanilidhydroksaminsyre og fremgangsmate for fremstilling av slike
TW200639156A (en) New compounds
PH12014502407B1 (en) New alfentanil composition for the treatment of acute pain
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
MX2009005804A (es) Composicion farmaceutica de memantina.
MX2007014963A (es) Composicion de liberacion modificada de al menos una forma de venlafaxina.
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
WO2006110810A3 (en) Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.